1418 related articles for article (PubMed ID: 35182880)
1. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
[TBL] [Abstract][Full Text] [Related]
2. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
[TBL] [Abstract][Full Text] [Related]
3. Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects.
Maniscalco GT; Ferrara AL; Liotti A; Manzo V; Di Battista ME; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Alfieri G; Di Iorio W; Della Rocca G; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Jun; 62():103800. PubMed ID: 35462168
[TBL] [Abstract][Full Text] [Related]
4. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
Meyer-Arndt L; Braun J; Fauchere F; Vanshylla K; Loyal L; Henze L; Kruse B; Dingeldey M; Jürchott K; Mangold M; Maraj A; Braginets A; Böttcher C; Nitsche A; de la Rosa K; Ratswohl C; Sawitzki B; Holenya P; Reimer U; Sander LE; Klein F; Paul F; Bellmann-Strobl J; Thiel A; Giesecke-Thiel C
J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):960-971. PubMed ID: 35835468
[TBL] [Abstract][Full Text] [Related]
6. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
Front Immunol; 2022; 13():868915. PubMed ID: 35432335
[TBL] [Abstract][Full Text] [Related]
7. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
Front Immunol; 2021; 12():781843. PubMed ID: 34956211
[TBL] [Abstract][Full Text] [Related]
8. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455
[TBL] [Abstract][Full Text] [Related]
9. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
10. Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies.
Ozakbas S; Baba C; Dogan Y; Cevik S; Ozcelik S; Kaya E
Mult Scler Relat Disord; 2022 Feb; 58():103486. PubMed ID: 35032878
[TBL] [Abstract][Full Text] [Related]
11. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
12. The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Rabenstein M; Thomas OG; Carlin G; Khademi M; Högelin KA; Malmeström C; Axelsson M; Brandt AF; Gafvelin G; Grönlund H; Kockum I; Piehl F; Lycke J; Olsson T; Hessa T
Eur J Neurol; 2023 Dec; 30(12):3789-3798. PubMed ID: 37522464
[TBL] [Abstract][Full Text] [Related]
13. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L
J Neurol; 2023 May; 270(5):2380-2391. PubMed ID: 36933032
[TBL] [Abstract][Full Text] [Related]
14. In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
Achiron A; Mandel M; Dreyer-Alster S; Magalashvili D; Menascu S; Warszawer Y; Dolev M; Didikin M; Harari G; Sonis P; Falb R; Gurevich M
Mult Scler Relat Disord; 2023 Apr; 72():104616. PubMed ID: 36933299
[TBL] [Abstract][Full Text] [Related]
15. Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
Maniscalco GT; Liotti A; Ferrara AL; Prestipino E; Salvatore S; Di Battista ME; Moreggia O; Di Giulio Cesare D; Vastano R; Belardo M; Napolitano M; Ranieri A; Longo K; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Dec; 68():104371. PubMed ID: 36544318
[TBL] [Abstract][Full Text] [Related]
16. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
17. Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies.
Wallach AI; Schiebel M; Picone MA
Mult Scler Relat Disord; 2022 Jul; 63():103856. PubMed ID: 35636275
[TBL] [Abstract][Full Text] [Related]
18. Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.
Altieri M; Capuano R; Conte M; Donnarumma G; Grimaldi E; Coppola N; Galdiero M; d'Ambrosio A; Tedeschi G; Gallo A
Neurol Sci; 2022 May; 43(5):2947-2949. PubMed ID: 35171373
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
[TBL] [Abstract][Full Text] [Related]
20. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]